Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Articles|May 19, 2010
What's Race & Ethnicity Got To Do With It? For Insulin Regimens, A Lot
Is a once daily dose of insulin glargine or NPH the best treatment strategy for patients who are of Latino/Hispanic descent? Which ethnicity responds best to a lispro mix of 75/25 twice daily? With the brunt of type 2 diabetes affecting non-Caucasian populations, researchers shed light on treatment strategy efficacy across races and ethnicities.
Advertisement
Is a once daily dose of insulin glargine or NPH the best treatment strategy for patients who are of Latino/Hispanic descent? Which ethnicity responds best to a lispro mix of 75/25 twice daily? With the brunt of type 2 diabetes affecting non-Caucasian populations, researchers shed light on treatment strategy efficacy across races and ethnicities.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
4
Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms
5